Development and Investigation of Assays For Cardiovascular Risk Assessment
$0ZIAFY2014CLNIH
Clinical Center
Investigators
Linked publications & trials
Paper 28826575Paper 28486149Paper 28242049Paper 28228137Paper 27879324Paper 27840858Paper 27590105Paper 27235445Paper 27122601Paper 27055952Paper 26613945Paper 26559180Paper 26523981Paper 26483418Paper 26371381Paper 26071490Paper 25911071Paper 25692941Paper 25670364Paper 25634835Paper 25477346Paper 25239440Paper 25203718Paper 24914045Paper 24240064Paper 24233487Paper 23628525Paper 23386699Paper 23325471Paper 22981508Paper 22508840Paper 22402736Paper 21798543Paper 21554699Paper 21266551Paper 21228254Paper 20378768Paper 19965776Paper 19822139Paper 19796777Paper 11238308
Abstract
In the past year, we evaluated and implemented a new method for measuring lipoprotein subtractions and size by NMR. This test is now available through CRIS for other clinical investigators to use. Using a variety of clustering techniques, are investigating the grouping of patients based on their lipoprotein profile, as measured by NMR, with cardiovascular risk. We are also investigating the change in the NMR signal in response to adding exogenous lipoprotein modifying enzymes, such as Lipoprotein Lipase, to determine if this provides additional information related to cardiovascular risk. We also participated in a recently published meta analysis comparing ApoB versus NMR for assessing cardiovascular risk.
View original record on NIH RePORTER →